QBS10072S treatment demonstrated dose-dependent phosphorylation of H2AX in U251 and LN229 GBM cells (Figure 2C), indicating compound-induced DNA damage and confirming the mechanism of QBS10072S. The gene discussed is H2AX; the disease is glioblastoma.